Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. - Fiskus W; Mill CP; Piel J; Collins M; Hentemann M; Cuglievan B; Birdwell CE; Das K; Davis JA; Hou H; Jain A; Malovannaya A; et al. (HemaSphere, 2026)